New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
10:36 EDTTEVA, MYLMylan launches generic Nordette 28 tablets
Mylan (MYL) announced that its partner Famy Care Ltd. has received final approval from the FDA for its Abbreviated New Drug Application for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg. This product is the generic version of Teva Branded Pharmaceutical Products' (TEVA) Nordette 28 Tablets, which are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. The product will be distributed in the U.S. by Mylan Pharmaceuticals Inc., and the company is shipping product immediately.
News For MYL;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
10:00 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:46 EDTTEVA, MYLMylan buyout below $95/share favorable for Teva, says Leerink
Subscribe for More Information
08:20 EDTMYLMylan’s Piatt was developer at land where company built headquarters, WSJ says
Mylan’s vice chairman and lead independent director Rodney Piatt served as the main developer of the company’s Pittsburgh office park where it built new headquarters, the Wall Street Journal reports, citing property records. Just a day before Mylan unveiled plans to build its new headquarters in an office park near Pittsburgh in December 2013, a company owned by Mylan vice chairman and lead independent director Rodney Piatt sold a 7-acre site for $1 to an entity owned by Andrew Miller, a business partner in Southpointe II, the report says. The firm sold the same land to Mylan for $2.9M later that same day, the report says. Mylan says there was no need to disclosed Piatt’s connection to the real estate project since he and the company avoided any direct dealings with each other, the Wall Street Journal reports. The records obtained by the Journal show that a similar transaction occurred in May, when Mylan paid $9.2M to buy an adjacent 11 acres from Miller, whose firm previously purchased the land for $10 from a company partly owned by Piatt. Reference Link
07:43 EDTTEVABernstein specialty pharmaceutical analyst has analyst/industry conference call
Subscribe for More Information
06:30 EDTTEVATeva initiated with a Buy at BTIG
Subscribe for More Information
July 6, 2015
13:44 EDTMYL, TEVAMylan calls active after report of new Teva bid
Subscribe for More Information
12:31 EDTTEVA, MYLTeva to bump bid for Mylan up to $86-$88 per share, Bloomberg says
Teva (TEVA) plans to raise its takeover bid for Mylan (MYL) to $86 to $88 per share from the $82 per share it offered in April, reported Bloomberg, citing people with knowledge of the matter, who said the sweetened bid could be announced as soon as this week. Shares of Mylan are up 0.8% to $70.69 following the report, while Teva shares are up 0.3% to $61.74. Reference Link
12:22 EDTMYL, TEVAMylan jumps after Bloomberg report of new Teva bid
Subscribe for More Information
12:18 EDTTEVA, MYLTeva planning to raise Mylan bid to $86-$88/share, Bloomberg reports
Subscribe for More Information
July 2, 2015
09:50 EDTMYLThe Medicines Co. drops 3.2% to $27.43 in early trading
Subscribe for More Information
July 1, 2015
08:30 EDTTEVATeva launches generic Aggrenox capsules in the U.S.
Teva announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Aggrenox capsules had annual sales of approximately $457M in the United States, according to IMS data as of April.
08:11 EDTTEVATeva, Xenon provide update on TV-45070 Phase 2b study in OA pain
Subscribe for More Information
08:04 EDTTEVATeva, Xenon Pharmaceuticals provide update on TV-45070 Phase 2b study
Subscribe for More Information
08:01 EDTTEVA, MYLTeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
June 30, 2015
08:27 EDTTEVA, MYLPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
June 26, 2015
10:38 EDTTEVACourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVA, MYLEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:05 EDTTEVATeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
June 24, 2015
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use